{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T05:27:01Z","timestamp":1671773221861},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T00:00:00Z","timestamp":1494460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T00:00:00Z","timestamp":1494460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Spinal Cord Ser Cases"],"DOI":"10.1038\/scsandc.2017.19","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T14:39:52Z","timestamp":1494513592000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ceftolozane\/tazobactam for febrile UTI due to multidrug-resistant Pseudomonas aeruginosa in a patient with neurogenic bladder"],"prefix":"10.1038","volume":"3","author":[{"given":"Aur\u00e9lien","family":"Dinh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Davido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruxandra","family":"Calin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Paquereau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Duran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Bouchand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Ph\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Chartier-Kastler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Rottman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Pl\u00e9siat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00efs","family":"Potron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,11]]},"reference":[{"key":"BFscsandc201719_CR1","unstructured":"Cubist Pharmaceuticals Inc. Zerbaxa (ceftolozane\/tazobactam) for injection, for intravenous use (package insert). 2014. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206829lbl.pdf (accessed 19 September 2016)."},{"key":"BFscsandc201719_CR2","first-page":"215","volume":"6","author":"M-C Hong","year":"2013","unstructured":"Hong M-C, Hsu DI, Bounthavong M . Ceftolozane\/tazobactam: a novel antipseudomonal cephalosporin and \u03b2-lactamase-inhibitor combination. Infect Drug Resist 2013; 6: 215\u2013223.","journal-title":"Infect Drug Resist"},{"key":"BFscsandc201719_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12879-016-1484-4","volume":"16","author":"A Dinh","year":"2016","unstructured":"Dinh A, Toumi A, Blanc C, Descatha A, Bouchand F, Salomon J et al. Management of febrile urinary tract infection among spinal cord injured patients. BMC Infect Dis 2016; 16: 156.","journal-title":"BMC Infect Dis"},{"key":"BFscsandc201719_CR4","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1128\/AAC.01802-13","volume":"57","author":"DJ Farrell","year":"2013","unstructured":"Farrell DJ, Flamm RK, Sader HS, Jones RN . Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011\u20132012). Antimicrob Agents Chemother 2013; 57: 6305\u20136310.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFscsandc201719_CR5","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"J Solomkin","year":"2015","unstructured":"Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J et al. Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis 2015; 60: 1462\u20131471.","journal-title":"Clin Infect Dis"},{"key":"BFscsandc201719_CR6","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO . Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385: 1949\u20131956.","journal-title":"Lancet"},{"key":"BFscsandc201719_CR7","doi-asserted-by":"publisher","first-page":"e02136-16","DOI":"10.1128\/AAC.02136-16","volume":"61","author":"JJ Cast\u00f3n","year":"2016","unstructured":"Cast\u00f3n JJ, De la Torre \u00c1, Ruiz-Camps I, Sorl\u00ed ML, Torres V, Torre-Cisneros J . Salvage therapy with ceftolozane\/tazobactam for multidrug resistant Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2016; 61: e02136-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFscsandc201719_CR8","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1128\/AAC.03074-15","volume":"60","author":"B Miller","year":"2016","unstructured":"Miller B, Popejoy MW, Hershberger E, Steenbergen JN, Alverdy J . Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a randomized, double-blind, Phase 3 ceftolozane-tazobactam study. Antimicrob Agents Chemother 2016; 60: 4387\u20134390.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFscsandc201719_CR9","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/sc.2015.234","volume":"54","author":"A Dinh","year":"2016","unstructured":"Dinh A, Saliba M, Saadeh D, Bouchand F, Descatha A, Roux AL et al. Blood stream infections due to multidrug-resistant organisms among spinal cord-injured patients, epidemiology over 16 years and associated risks: a comparative study. Spinal Cord 2016; 54: 720\u2013725.","journal-title":"Spinal Cord"},{"key":"BFscsandc201719_CR10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1128\/AAC.47.5.1681-1688.2003","volume":"47","author":"JA Karlowsky","year":"2003","unstructured":"Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF . Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 1681\u20131688.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFscsandc201719_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2047-2994-3-32","volume":"3","author":"D Nathwani","year":"2014","unstructured":"Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V . Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2014; 3: 32.","journal-title":"Antimicrob Resist Infect Control"},{"key":"BFscsandc201719_CR12","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1128\/AAC.48.12.4606-4610.2004","volume":"48","author":"MD Obritsch","year":"2004","unstructured":"Obritsch MD, Fish DN, MacLaren R, Jung R . National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004; 48: 4606\u20134610.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFscsandc201719_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1086\/377200","volume":"37","author":"C-I Kang","year":"2003","unstructured":"Kang C-I, Kim S-H, Kim H-B, Park S-W, Choe Y-J, Oh M-D et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37: 745\u2013751.","journal-title":"Clin Infect Dis"},{"key":"BFscsandc201719_CR14","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1128\/AAC.00338-07","volume":"51","author":"TP Lodise","year":"2007","unstructured":"Lodise TP, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51: 3510\u20133515.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFscsandc201719_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1055\/s-0034-1396907","volume":"36","author":"K McCarthy","year":"2015","unstructured":"McCarthy K . Pseudomonas aeruginosa: evolution of antimicrobial resistance and implications for therapy. Semin Respir Crit Care Med 2015; 36: 44\u201355.","journal-title":"Semin Respir Crit Care Med"},{"key":"BFscsandc201719_CR16","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1128\/AAC.00750-12","volume":"56","author":"L Morata","year":"2012","unstructured":"Morata L, Cobos-Trigueros N, Mart\u00ednez JA, Soriano A, Almela M, Marco F et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2012; 56: 4833\u20134837.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFscsandc201719_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1128\/AAC.00901-06","volume":"51","author":"RB Osih","year":"2007","unstructured":"Osih RB, McGregor JC, Rich SE, Moore AC, Furuno JP, Perencevich EN et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2007; 51: 839\u2013844.","journal-title":"Antimicrob Agents Chemother"},{"key":"BFscsandc201719_CR18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1592\/phco.31.6.598","volume":"31","author":"KA Traugott","year":"2011","unstructured":"Traugott KA, Echevarria K, Maxwell P, Green K, Lewis JS . Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy 2011; 31: 598\u2013608.","journal-title":"Pharmacotherapy"},{"key":"BFscsandc201719_CR19","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1592\/phco.2005.25.10.1353","volume":"25","author":"MD Obritsch","year":"2005","unstructured":"Obritsch MD, Fish DN, MacLaren R, Jung R . Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005; 25: 1353\u20131364.","journal-title":"Pharmacotherapy"},{"key":"BFscsandc201719_CR20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/jac\/44.5.689","volume":"44","author":"S Oie","year":"1999","unstructured":"Oie S, Sawa A, Kamiya A, Mizuno H . In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. J Antimicrob Chemother 1999; 44: 689\u2013691.","journal-title":"J Antimicrob Chemother"},{"key":"BFscsandc201719_CR21","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/jac\/dkg478","volume":"52","author":"S Oie","year":"2003","unstructured":"Oie S, Uematsu T, Sawa A, Mizuno H, Tomita M, Ishida S et al. In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 2003; 52: 911\u2013914.","journal-title":"J Antimicrob Chemother"},{"key":"BFscsandc201719_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1086\/650482","volume":"50","author":"TM Hooton","year":"2010","unstructured":"Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America (IDSA). Clin Infect Dis 2010; 50: 625\u2013663.","journal-title":"Clin Infect Dis"}],"container-title":["Spinal Cord Series and Cases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/scsandc201719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/scsandc201719","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/scsandc201719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/scsandc201719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T16:30:44Z","timestamp":1671726644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/scsandc201719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,11]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,10,5]]}},"alternative-id":["BFscsandc201719"],"URL":"https:\/\/doi.org\/10.1038\/scsandc.2017.19","relation":{},"ISSN":["2058-6124"],"issn-type":[{"value":"2058-6124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,11]]},"assertion":[{"value":"8 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"17019"}}